Ground-glass opacity showed response to immunotherapy in cancer patients. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback